12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tegobuvir: Interim Phase II data

Interim data from the open-label, U.S. Phase II Study 120 trial in 141 treatment-naïve patients with chronic HCV genotype 1 infection showed that 74 patients receiving an all-oral regimen of high-dose GS-5885, tegobuvir, GS-9451 and ribavirin achieved HCV RNA levels <25 IU/mL at week 2. In 27 evaluable patients who stopped treatment at week 12, 96% achieved an SVR 4 weeks after the end of treatment....

Read the full 326 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >